See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated

AstraZeneca Article Archives

March 2014

FDA Delays Final OK for Type 2 Drug Empagliflozin

The FDA will delay allowing the type 2 drug empagliflozin to enter the U.S. market until "previously observed deficiencies" at the plant where it is manufactured are fixed.

comments 0 comments - Posted Mar 23, 2014

January 2014

FDA OKs Dapagliflozin as Type 2 Drug

The Food and Drug Administration has approved the entry of dapagliflozin, a drug for treating type 2 diabetes, into the U.S. market.

comments 0 comments - Posted Jan 9, 2014

September 2013

Dapagliflozin Teams Well With Metformin, Sulfonylurea

According to researchers, dapagliflozin, a diabetes drug developed jointly by two pharmaceutical companies has shown significant benefits when teamed with metformin and sulfonylurea.

comments 0 comments - Posted Sep 28, 2013

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.